Published in Ann Intern Med on December 01, 1985
Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest (1988) 0.91
Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis. J Clin Invest (1991) 0.91
Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest (1993) 0.84
Kinetic studies on the effect of heparin and fibrin on plasminogen activators. Biochem J (1988) 0.83
Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 13.93
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med (2000) 5.43
Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci U S A (1987) 4.87
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Compensation to a department of medicine and its faculty members for the teaching of medical students and house staff. N Engl J Med (1996) 4.49
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation (1998) 3.92
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82
Association between myeloperoxidase levels and risk of coronary artery disease. JAMA (2001) 3.74
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation (1990) 3.49
Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest (1976) 3.42
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes. Circulation (1996) 3.32
Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) (1977) 3.20
Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med (1980) 3.12
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol (2001) 2.99
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol (1988) 2.60
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med (1990) 2.48
Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42
Therapeutic defibrination in the treatment of thrombotic disease. Lancet (1968) 2.40
The nephrotic syndrome associated with secondary syphilis. An immune deposit disease. Am J Med (1970) 2.37
Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol (1999) 2.36
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J (2001) 2.30
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
C-reactive protein: a 'golden marker' for inflammation and coronary artery disease. Cleve Clin J Med (2001) 2.17
Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem (1989) 2.14
Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation (2001) 2.12
Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA (1997) 2.11
Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol (1996) 2.11
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA (2000) 2.11
Myonecrosis after revascularization procedures. J Am Coll Cardiol (1998) 2.11
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation (1995) 2.08
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08
Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol (1996) 2.07
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06
Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation (1995) 2.06
Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. Stroke (1998) 2.03
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03
The last word on GUSTO, for now. Ann Intern Med (1994) 2.02
Practice guidelines and physician scorecards: grading the graders. Cleve Clin J Med (1997) 2.00
Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med (1986) 1.94
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet (2004) 1.94
A comparative analysis of pulmonary perfusion scans with pulmonary angiograms. Am Heart J (1976) 1.93
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med (1995) 1.93
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1990) 1.90
Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury. Circulation (1986) 1.88
Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) (1981) 1.88
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Relation of regional cross-fiber shortening to wall thickening in the intact heart. Three-dimensional strain analysis by NMR tagging. Circulation (1994) 1.84
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83
Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation (1990) 1.83
Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol (1992) 1.82
Current concepts: guidelines for the use of thrombolytic agents. N Engl J Med (1979) 1.82
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.80
Echocardiographic assessment of a normal adult aging population. Circulation (1977) 1.80
The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol (1992) 1.79
Exercise cardiac output is maintained with advancing age in healthy human subjects: cardiac dilatation and increased stroke volume compensate for a diminished heart rate. Circulation (1984) 1.79
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation (2000) 1.79
Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol (1978) 1.79
Coronary-artery stents--gauging, gorging, and gouging. N Engl J Med (1998) 1.78
The clinical features of submassive and massive pulmonary emboli. Am J Med (1977) 1.77
Cellular mechanisms of myocardial infarct expansion. Circulation (1988) 1.77
Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises. JAMA (1992) 1.76
Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation (1994) 1.76
Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation (1990) 1.74
Noninvasive quantification of left ventricular rotational deformation in normal humans using magnetic resonance imaging myocardial tagging. Circulation (1990) 1.74
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J (2000) 1.73
Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am J Physiol (1982) 1.72
Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. N Engl J Med (1979) 1.71
Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol (1993) 1.70
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation (2001) 1.70
Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J (2002) 1.69
Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. Am J Cardiol (2000) 1.69
Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation (1998) 1.66
Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation (1990) 1.66
The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med (1990) 1.66